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Abstract
Neuroimmune gene induction is involved in many brain pathologies including addiction. Although increased expression of
proinflammatory cytokines has been found in ethanol-treated mouse brain and rat brain slice cultures as well as in post-
mortem human alcoholic brain, the mechanisms remain elusive. High-mobility group box 1 (HMGB1) protein is a nuclear
protein that has endogenous cytokine-like activity. We previously found increased HMGB1 in post-mortem alcoholic human
brain as well as in ethanol treated mice and rat brain slice cultures. The present study investigated the mechanisms for
ethanol-induced release of HMGB1 and neuroimmune activation in a model of rat hippocampal-entorhinal cortex (HEC)
brain slice cultures. Ethanol exposure triggered dose-dependent HMGB1 release, predominantly from neuronal cells.
Inhibitors of histone deacetylases (HDACs) promoted nucleocytoplasmic mobilization of HDAC1/4 and HMGB1 resulting in
increased total HMGB1 and acetylated HMGB1 release. Similarly, ethanol treatment was found to induce the translocation of
HDAC1/4 and HMGB1 proteins from nuclear to cytosolic fractions. Furthermore, ethanol treatment reduced HDAC1/4 mRNA
and increased acetylated HMGB1 release into the media. These results suggest decreased HDAC activity may be critical in
regulating acetylated HMGB1 release from neurons in response to ethanol. Ethanol and HMGB1 treatment increased mRNA
expression of proinflammatory cytokines TNFa and IL-1b as well as toll-like receptor 4 (TLR4). Targeting HMGB1 or microglial
TLR4 by using siRNAs to HMGB1 and TLR4, HMGB1 neutralizing antibody, HMGB1 inhibitor glycyrrhizin and TLR4 antagonist
as well as inhibitor of microglial activation all blocked ethanol-induced expression of proinflammatory cytokines TNFa and
IL-1b. These results support the hypothesis that ethanol alters HDACs that regulate HMGB1 release and that danger signal
HMGB1 as endogenous ligand for TLR4 mediates ethanol-induced brain neuroimmune signaling through activation of
microglial TLR4. These findings provide new therapeutic targets for brain neuroimmune activation and alcoholism.
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Introduction
Neuroimmune activation in brain has been hypothesized to
contribute to brain damage and behavioral changes associated
with alcohol consumption. In recent years, many studies have
reported that chronic alcohol consumption can increase proin-
flammatory cytokines and innate immune gene expression in the
brain [1,2]. Increased cytokines and other neuroimmune genes
have been reported in human post-mortem alcoholic brain [3,4],
as well as following ethanol treatment of animals [5,6] and brain
slice cultures [4,7]. Recent studies suggest activation of brain
neuroimmune signaling induces changes in mood and drinking
behavior and increases risk of alcoholism as well as alcoholic
neurodegeneration [1]. Genetic analysis of ethanol preferring rats
and mice reveals increased expression of multiple innate immune
genes associated with preferring to drink ethanol [8]. Further,
studies have demonstrated that Toll-like receptor 4 (TLR4) is
critical for ethanol-induced neuroimmune activation, neurode-
generation and behavioral pathology [2,6]. Treatment of mice
with classic TLR4 ligand lipopolysaccharide (LPS) shows an
increase in ethanol consumption and preference that persists for
months [9] consistent with the prolonged brain neuroimmune
response following LPS treatment of mice [10]. Central amygdala
infusion of a TLR4 siRNA vector (pHSVsiLTLR4a) also inhibited
binge drinking in rats [11]. Recent studies support the hypothesis
that high mobility group box 1 (HMGB1) protein, an endogenous
cytokine that can activate toll-like receptors including TLR4, is
linked to ethanol-induced increase in expression of brain
neuroimmune genes [12]. Therefore, it is conceivable that ethanol
exposure may trigger release of endogenous TLR4 ligand
HMGB1 contributing to ethanol-induced neuroimmune signaling
through TLR4 receptor activation.
Release of HMGB1 can occur as an active process stimulated by
cellular signaling processes or as a result of cell death. The release
of HMGB1 by dying cells is thought to drive the necrotic cell
death inflammatory response [13,14,15]. Active release of
HMGB1 involves receptor signaling without cell death and has
been studied primarily in immune cells such as monocytes [16,17]
and in hepatocytes [18]. Receptor stimulated release of HMGB1
involves acetylation that regulates nuclear and cytoplasmic levels
of HMGB1 apparently through actions on nuclear enzymes that
regulate protein acetylation, e.g. histone deacetylases (HDAC) and
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histone acetylases (HAT) [18,19]. Active cellular HMGB1 release
involves migration from the nucleus to lysosome-like vesicles that
protect HMGB1 from proteolysis in the cytoplasm [16,18].
Calcium/calmodulin-dependent protein kinase (CaMK) in mono-
cytes activates HMGB1 migration to cytosolic vesicles and triggers
exocytosis of vesicles releasing HMGB1 into the extracellular
space [20,21]. Recent studies have suggested that brain HMGB1 is
highly expressed in neurons and is released by neurons
[12,22,23,24]. These findings are consistent with brain releasing
HMGB1 that impacts neuronal signaling.
To investigate HMGB1 release in brain in response to ethanol
exposure we used an ex vivo hippocampal-entorhinal cortex (HEC)
brain slice culture model that contains all brain cell types and
maintains the morphology and local circuits that could contribute
to signaling. We report here that HMGB1 appears to be highly
expressed in mature and immature neurons in HEC slices.
Ethanol exposure triggered release of HMGB1 into the culture
media and released HMGB1 was primarily acetylated HMGB1.
Both ethanol and HDAC inhibitors increased HMGB1 and
HDAC in cytosolic fractions and reduced levels in nuclear
fractions suggesting that HDAC inhibition mobilizes protein
migration from nuclear to cytoplasmic compartments. We found
that ethanol decreased HDAC expression and increased acetylated
HMGB1, consistent with HDAC regulating HMGB1 release in
brain. Ethanol treatment induced proinflammatory cytokine genes
as well as HMGB1 and TLR receptors. Targeting HMGB1 and/
or TLR4 receptors blocked ethanol-induced neuroimmune
activation supporting the hypothesis that ethanol induces HMGB1
release, activating TLR4-mediated neuroimmune signaling. These
studies suggest that brain HDACs are linked to HMGB1-TLR4
neuroimmune signaling. The release of HMGB1 by ethanol and/
or other factors provides new therapeutic targets for brain




All protocols followed in this study were carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. The animal protocol was approved by the Institutional
Animal Care and Use Committee (IACUC) at University of North
Carolina at Chapel Hill (IACUC ID: 13-050). All efforts were
made to minimize suffering.
Hippocampal-entorhinal Cortical Slice Culture
Organotypic hippocampal-entorhinal cortical (HEC) slice cul-
tures were prepared as described previously [25]. Briefly, Slices
were placed onto a 30 mm diameter membrane tissue insert and
cultured with medium containing 75% MEM with 25 mM
HEPES and Hank’s salts +25% horse serum (HS) +5.5 g/L
glucose +2 mM L-glutamine in a humidified 5% CO2 incubator at
36.5uC for 7 days in vitro (DIV), followed by 4 DIV in medium
containing 12.5% HS and then in serum-free medium supple-
mented with N2 till the end of experiment. The cultures after 14
DIV were used for experiments. Drug treatments were done
during the final 4–7 DIV in serum-free N2 medium.
Drug and Ethanol Treatments
All drug treatments were performed in serum-free N2 supple-
mented medium. Ethanol treatment with the indicated concen-
Table 1. Primer sequences for quantitative PCR analysis.















Figure 1. Ethanol increases HMGB1 expression and release. A:
ELISA measurements indicate ethanol dose-dependently increase
HMGB1 release into culture medium compared with Control (*p,
0.05; n = 3); B: Western blotting of the whole cell lysate show HMGB1
protein level was increased progressively over time period in response
to ethanol; C: RT-PCR analysis show ethanol-induced mRNA expression
and HMGB1 as well as TLR4 and TLR2 (*p,0.05 compared with Control;
n = 3).
doi:10.1371/journal.pone.0087915.g001
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trations occurred in a desiccator containing 300 ml water
saturated with equal concentrations of ethanol to balance
evaporation of ethanol from the media. HMGB1 was purchased
from Invitron (Invitrogen, CA) or Sigma (St. Louis, MO) and only
one batch from Sigma (Cat#H4652, Lot#090M4056) show
potent inflammatory activity. At the end of the experiments, media
were collected and slices were removed for further analysis.
ELISA Measurements of HMGB1
Media HMGB1 levels from each experiment were determined
with ELISA kit (IBL, Germany) according to manufacturer’s
instruction. Briefly, total of 50 ml of culture medium from each
sample was used for ELISA. All samples were run in triplicate.
Confocal Analysis
At the end of experiments, slice cultures were removed and
fixed with 4% paraformaldehyde+5% sucrose in 0.01 M PBS and
placed in cold room overnight. Free-floating slices were used for
double immunofluorescent staining. Specific cellular markers used
include anti-neuronal-specific nuclear protein (NeuN) for neurons,
Iba-1 for microglia and GFAP for astrocytes. All primary
antibodies were incubated for 48 hrs at 4uC. Either Alexa Fluor
594 or Alexa Fluor 488 secondary antibodies (1:2000; Molecular
Probes, Eugene, OR) were used for immunofluorescent staining
and incubated for 1 hr at room temperature. The slices were cover
slipped with anti-fade mounting medium (pro-long; Molecular
Probes). Confocal analysis was performed using a LeicaSP2 AOBS
Upright Laser Scanning Confocal in the Michael Hooker
Microscopy Facility, UNC.
Western Blotting
Cell lysates were prepared from the entire HEC slices. Briefly,
HEC slices were incubated in lysis buffer (10 mM HEPES,
1.5 mM MgCl2, 10 mM KCl, pH7.9) plus protease inhibitor
cocktail (Sigma) for 15 min then disrupted with sonication (3 time,
2 min apart in ice). After centrifugation of the slice homogenate,
the supernatant were collected. For preparation of cytosolic and
nuclear fraction of protein extracts, the pellet was disrupted again
in an extraction buffer and the supernatants of nuclear fraction
were collected after centrifugation. The protein concentrations
were determined by using the Bio-Rad Protein Assay (Bio-Rad).
For Western blotting, an equal amount of protein was mixed with
Figure 2. Neuronal expression of HMGB1. Representative confocal merger images showing A: double immunofluorescent staining with anti-
HMGB1 (red) and anti-NeuN (green), a marker for mature neurons. Majority of NeuN+ neurons coexpressing HMGB1 (yellow); B: double
immunofluorescent staining with anti-HMGB1 (red) and anti-doubleCortin (DCX, green), a marker for immature neurons. HMGB1 is located in the
nuclear of majority DCX+ neurons. Mobilization and translocation of nuclear HMGB1 in HEC slices was further depicted from treatment of Control (C),
ethanol (D), TSA (E), Scriptaid (F), LPS (G) and NMDA (H). Nuclear mobilization and/or cytoplasm translocation in neurons were indicated by arrows
(original magnification 80x in A–B: 320x in C–H).
doi:10.1371/journal.pone.0087915.g002
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10 ml 5x loading buffer, and separated using a 4–15% Tris mini-
gel (Bio-Rad), then transferred onto a PVDF membrane. After
blocking with LI-COR blocking buffer overnight, the membrane
was probed with mouse anti-HDAC1 (Santa Cruz, 1:200) and
rabbit anti-HDAC4 Abcam, 1:250) at 4uC overnight. After
washing, membrane was incubated with goat anti-mouse and
anti-rabbit second antibodies coupled with green or red fluores-
cence from LI-COR Bioscience then scanned with the Odyssey
machine (Lincoln, NE). The membranes were then stripped with
Newblot PVDF stripping buffer (LI-COR) and re-probed with
rabbit anti-HMGB1antibody (1:500, Abcam) and mouse anti-b-
actin (1:500, Santa Cruz) at 4uC overnight. The membranes were
then detected with the same secondary antibodies as mentioned
above.
Co-immunoprecipitation
Immunoprecipitation was performed to detect the status of
acetylated HMGB1 in culture medium using a catch and release
kit (Millipore, USA) according to the manufacturer’s instructions.
Briefly, a total 250 ml of culture medium from each sample was
Figure 3. HDAC inhibitors increase HMGB1 release. A: Shown are mean 6 SEM of media HMGB1 levels from a representative dose dependent
study indicating broad HDAC inhibitor TSA and selective HDAC1 inhibitor MS-275 trigger active release of neuronal HMGB1 into medium (*p,0.01
compared with control; n = 3). C: ELISA measurements of media HMGB1 from cultures treated with various HDAC inhibitors alone or co-presence of
ethanol. Treatments of HEC slices for 4 days with ethanol in the absence or presence of inhibitors including TSA (1 mM), MS-275 (5 mM), sodium
butylate (SB, 100 mM) and vaproic acid (VPA, 100 mM) increase media HMGB1 level but only TSA and MS-275 appears to potentiate ethanol action
(*p,0.01 compared with Control; #p,0.001 compared with EtOH. n = 3).
doi:10.1371/journal.pone.0087915.g003
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incubated with 5 mg of antibodies against acetyl-lysine (Cell
Signaling, USA) and 10 ml affinity ligand for 1 hr at room
temperature. Proteins were eluted in its native form and subjected
to Western blot analysis. The blots were probed with rabbit anti-
HMGB1 (1:500, Abcam).
TLR4 or HMGB1 Knockdown with siRNAs
Rat TLR4 and HMGB1 siRNA as well as negative control
siRNA were purchased from Ambion (Ambion, Grand Island,
NY). The protocol of transfection in HEC slices has been
described previously [26]. Briefly, the transfection mixture was
added to serum-free N2 medium at a final concentration of 20 nM
siRNA +6 ml Lipofectamine 2000 to a total volume of
1.2 ml(600 ml on top of the slices and 600 ml at bottom of the
slice culture). Vehicle controls were treated with the same N2
medium containing negative control siRNA. After transfection for
24 hrs, siRNA-containing medium was replaced with regular
serum-free N2-supplemented medium and the slices were cultured
in the absence or presence of ethanol (100 mM) for 4 days. At the
end of the experiments the slices were removed for real-time PCR
analysis.
RNA Isolation, Reverse Transcription and Real Time
Quantitative RT-PCR
For each specific experiment, the slices were removed at the end
of the experiments for purification of total RNA using the RNeasy
Mini Kit (Qiagen Inc., CA). The total amount of RNA was
quantified by spectrophotometry at 260 nm. For reverse tran-
scription, 2 mg of RNA was used to synthesize the first strand of
cDNA using random primers (Invitrogen) and reverse transcrip-
tase Moloney murine leukemia virus (Invitrogen). After a 1:2
dilution with water, 2 ml of the first strand cDNA solution was
used for RT-PCR. The primer sequences for real time RT-PCR
were designed by Integrated DNA Technologies (Coralville, IA)
and listed in Table 1. SYBER Green Supermix (AB system, UK)
was used as a RT-PCR solution. The real time RT-PCR was run
with initial activation for 10 min at 95uC and followed by 40 cycles
of denaturation (95uC, 40 s) annealing (58uC, 45 s) and extension
(72uC, 40 s). All experiments were run in triplicate. The threshold
cycle (CT) of each target product was determined and normalized
to internal standard b-actin.
Statistical Analysis
Data are presented as a mean 6 S.E.M values from the
indicated number of slice preparations in an experiment.
Statistical comparisons were made with ANOVA and the
difference between the experimental groups was further compared
by using post hoc Fisher PLSD test. In cases with a low N, SAS
permutation tests were used to determine to confirm ANOVA
significance.
Results
Ethanol Release of HMGB1 from HEC Brain Slice Cultures
To gain insight into the mechanisms of ethanol induced
HMGB1 release, HEC slices were treated with various ethanol
concentrations. Ethanol concentration response curves find a
significant increase in media HMGB1 in a concentration
dependent manner that at the highest concentration studied, a
high binge drinking concentration, increased media HMGB1
about 4 fold (Figure 1A). To determine if cell death contributed to
ethanol induced HMGB1 release we used propidium iodide (PI), a
sensitive marker of cell death. Ethanol (100 mM) after 4 days did
not alter PI intensity (PI intensity: 22.962.6 control; 26.363.1
ethanol; n = 8), suggesting cellular HMGB1 release in the absence
of cell death. A time course of ethanol (100 mM)-induced
HMGB1 release finds significant increases in media at 4 hrs that
progressively increase over 4 days of exposure (data not shown).
Figure 4. TSA-induced cytoplasmic mobilization of HDAC1 and
4 as well as HMGB1. A: Western blot analysis of HEC slice cytosolic
protein extracts for HDAC1, HDAC4 and HMGB1 from a representative
experiment with ethanol (100 mM) and TSA (1 mM). B: Western blot
analysis of HEC slice nuclear protein extracts for HDAC1, HDAC4 and
HMGB1 from the same experiments shown in A. C: Co-immunoprecip-
itation analysis of culture medium for acetylated HMGB1 level. Anti-
rabbit IgG was used as a negative control.
doi:10.1371/journal.pone.0087915.g004
Figure 5. Inhibition of HDAC1 by MS-275 causing cytoplasmic
mobilization of HDAC1 and HMGB1. A: Western blot analysis of
HEC slice cytosolic protein extracts for HDAC1 and HMGB1 from a
representative experiment with ethanol (100 mM) and MS-275 (5 mM).
B: Western blot analysis of HEC slice nuclear protein extracts for HDAC1,
HDAC4 and HMGB1 from the same experiments shown in A. C: Co-
immunoprecipitation analysis of culture medium for acetylated HMGB1
level. Anti-rabbit IgG was used as a negative control.
doi:10.1371/journal.pone.0087915.g005
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Western blot analysis of whole HEC slice lysates find ethanol
treatment progressively increases the amount of HMGB1 protein
(Figure 1B). In addition, ethanol treatment increased mRNA of
HMGB1 as well as the HMGB1 responsive receptors, TLR4 and
TLR2 (Figure 1C). These findings indicate ethanol increases
HMGB1 protein and mRNA in HEC brain slices and increases
media HMGB1 independent of cell death consistent with active
release of HMGB1.
Figure 6. Effects of ethanol on HDAC mRNA and protein expression. A: Shown are mean 6 SEM of HDAC1 and HDAC4 mRNA levels from a
representative time course study. Ethanol exposure inhibits both HDAC1 and HDAC4 mRNA expression (*p,0.05 compared with control; n = 3). B:
HDAC immunoreactivity (IR) was examined. Shown in bar graph (left) indicate both ethanol and TSA reduce HDAC4 IR in hippocampus (*p,0.05
compared with Control, n = 6). Representative images of HDAC4 IR were depicted from both control (a–b) and ethanol-treated (c–d) slices as
indicated at 20x and 40x magnification. C: Representative confocal images of double immunofluorescent staining with HDAC4 (red) and neuronal
marker NeuN (green) (a–b) and HMGB1 (c) indicating nuclear localization of HDAC4 in neuronal cells from control slices (a from dentate gyrus; b from
hippocampal CA field; c from dentate gyrus). Original magnification 80x.
doi:10.1371/journal.pone.0087915.g006
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Predominant Neuronal Expression and Release of HMGB1
in HEC Slice
To investigate the cell type expression of HMGB1 in HEC
brain slice cultures, we performed double immunofluorescent
staining and confocal analysis using cell specific markers, NeuN for
mature neurons; doubleCortin (DCX) for immature neurons;
GFAP for astrocytes; and Iba-1 for microglial cells. As shown in
Figure 1, HMGB1+ staining in HEC brain slice cultures is
detected in nuclei of NeuN+ mature neuronal cell (94.7%61.8%
in total 1824 NeuN+ cells counted), similar to histochemical
findings in mouse and postmortem human brain [12]. Interest-
ingly, we also found HMGB1 colocalized with DCX+ immature
neurons (96.5%62.1 in total 1086 DCX+ cells counted)
(Figure 2B). DCX is generally considered to be a marker for
neuroprogenitors of hippocampal dentate gyrus neuroprogenitors
in brain [27] as well as in this model [4]. To our surprise, HMGB1
rarely co-localized with Iba-1+ microglial cells (data not shown).
HMGB1 appears to express in the nuclei of some astrocyte
GFAP+ astrocytes (data not shown). These data suggest HMGB1
is highly expressed in neurons and neuroprogenitors in HEC brain
slice cultures. Neuronal release of HMGB1 is further examined
with double immunofluorescent staining and confocal analysis
from HEC slices treated with ethanol, LPS, NMDA and HDAC
inhibitors TSA and Scriptaid. Ethanol treatment decreased the
intensity of nuclear HMGB1 staining with no other visible
differences in neurons. Depending on the degree of insult,
different stages of nuclear HMGB1 mobilization in hippocampal
CA neurons were observed, from mobilization without cell death
in ethanol and TSA treatments (D–E, G) to complete depletion of
nuclear HMGB1 in dying neurons treated with Scriptaid (F) and
NMDA (H). These results suggest predominant neuronal source of
HMGB1 in this model.
Inhibition of HDACs Releases HMGB1
In monocytes [19,21] and hepatocytes [18] HMGB1 synthesis
and release increase simultaneously with increased HMGB1
acetylation. To determine if inhibition of HDAC impacts HMGB1
release HEC slices were treated with HDAC inhibitors trichostatin
A (TSA), sodium butyrate (SB), valproic acid (VPA) and MS-275.
All HDAC inhibitors increased release of HMGB1 (Figure 3).
TSA, a pan-HDAC inhibitor, as well as MS-275, a specific
HDAC1 inhibitor, increased HMGB1 release in a concentration
dependent manner (Figure 3A). Ethanol alone increased HMGB1
release, however, combinations of HDAC inhibitors with ethanol
were less than additive consistent with shared mechanisms of
HMGB1 release (Figure 3B). These findings are consistent with
HDAC regulating HMGB1 acetylation and release in brain.
HDACs Alter Nuclear-cytosol Distribution and Release of
HMGB1
HMGB1 and HDACs have been shown to shuttle from nuclear
to cytosolic compartments in hepatocytes [18]. To determine if
HDACs alter nuclear and cytosolic distribution in brain cells we
treated HEC slices with TSA or MS-275 and separated cytosolic
and nuclear fractions followed by Western blot analysis. We
assessed nuclear-cytoplasmic changes in distribution of HMGB1 as
well as HDAC1 and HDAC4. Controls find greater protein levels
in HMGB1, HDAC1 and HDAC4 nuclear fractions than cytosolic
fractions (Figure 4 and 5). Treatment of HEC slices with TSA,
ethanol and combined ethanol+TSA increased HMGB1protein in
cytoplasmic fractions (Figure 4A). Ethanol also slightly increased
cytosolic HDAC1 and HDAC4. TSA markedly increased HDAC1
and HDAC4 in the cytosol, and combined ethanol-TSA increased
cytosolic protein with clearly decreasing nuclear protein levels
Figure 7. Western blot analysis of HDAC1 and HDAC4 as well as
acetylated HMGB1. A: Western blot analysis of HEC slice cytosolic
protein extracts for HDAC1, HDAC4 and HMGB1 from a representative
ethanol time course experiment. B: Western blot analysis of HEC slice
nuclear protein extracts for HDAC1, HDAC4 and HMGB1 from the same
experiments shown in A. C: Co-immunoprecipitation analysis of culture
medium for acetylated HMGB1 level. Anti-rabbit IgG was used as a
negative control.
doi:10.1371/journal.pone.0087915.g007
Figure 8. Exogenous HMGB1 induces expression of proinflam-
matory genes. HEC slices were treated with HMGB1 (500 ng/ml) for
96 hrs. and then harvested for detection of proinflammatory cytokine
gene expression. Shown are mean 6 SEM of cytokines TNFa and IL-b
mRNA levels from a representative experiment. Treatment of HEC slices
with exogenous HMGB1 induced significant increase in cytokine gene
expression. Proinflammatory activity of HMGB1 is abolished by
blockade of TLR4 with antagonists Lps-Rs and naltrexone or by
knocking down TLR4 with specific siRNA (*p,0.01 compared with
Control; #p,0.05 compared with HMGB1 group, n = 3).
doi:10.1371/journal.pone.0087915.g008
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(Figure 4B). MS-275, a selective HDAC1 inhibitor, similarly
increased cytosolic HMGB1 and HDAC1 (Figure 5A). These
findings support the hypothesis that HDAC inhibitors and ethanol
increase acetylation of HMGB1 leading to increased cytoplasmic
HMGB1 and subsequent release. This hypothesis suggests released
HMGB1 should be acetylated HMGB1. To assess acetylation of
released HMGB1 we used co-immunoprecipitation (IP) of media
with acetyl-lysine antibodies and then performed Western blots to
determine levels of acetylated HMGB1. Treatment with ethanol,
HDAC inhibitors TSA (Figure 4C) and MS-275 (Figure 5C),
clearly increased acetylated HMGB1 level in media and combi-
nations of ethanol with HDAC inhibitors, markedly increased
acetylated HMGB1 release. These findings are consistent with
HDAC inhibitors and ethanol increasing secretion of acetylated
HMGB1.
Ethanol Modulation of HDAC Activity
Ethanol treatment mimicked HDAC inhibitor treatment
prompting experiments to examine the effects of ethanol on
HDAC activity in HEC brain slice cultures. Ethanol treatment
reduced HDAC mRNA (Figure 6-A). HDAC4 mRNA was
decreased by about 50% after 4 hrs of ethanol treatment whereas
HDAC1 was decreased after 48 hrs. Both remained suppressed for
up to 96 hrs of ethanol treatment. Immunohistochemical analysis
further confirmed that ethanol treatment significantly reduces
HDAC4+IR (Figure 6-B) corresponding with the decrease in
mRNA. Double immunofluorescent labeling reveals nuclear
localization of HDAC4 in many NeuN+ neuronal cells and co-
nuclear localization with HMGB1 in neurons (Figure 6-C).
Separation of cytosolic and nuclear fractions after various time
points of ethanol treatment finds increased cytosolic HDAC
proteins coinciding with decreased nuclear HDAC level
(Figure 7A–B). Changes in nuclear and cytosolic HDAC are
apparent after a little as 4 hrs of ethanol treatment.
Consistent with ethanol disrupting HDAC activity and releasing
acetylated HMGB1, ethanol treatment for as little as 4 hrs
Figure 9. HMGB1-mediated ethanol neuroimmune activation.
A: HEC slices were exposed to ethanol (100 mM) for 4 days in the
absence or presence of anti-HMGB1 neutralizing antibody. Chicken IgY
(10 mg/ml) was used as control antibody for HMGB1 neutralization.
Shown are mean 6 SEM of proinflammatory cytokine TNFa and IL-1b
mRNA levels, relative to chicken IgY-treated control. Ethanol induction
of TNFa and IL-1b mRNA is blocked by HMGB1 neutralizing antibody
(*p,0.01 compared to Control;#p,0.05 compared with EtOH; n = 3). B:
HMGB1 inhibitor glycyrrhizin (Glyc) was applied to the cultures during
ethanol (100 mM) treatment for 4 days. Shown are mean 6 SEM of
proinflammatory cytokine TNFa and IL-1b mRNA levels from a
representative experiment. Ethanol induction of TNFa and IL-1b mRNA
is completely blocked by glycyrrhizin (*p,0.001 compared to Control;
#p,0.0001 compared with EtOH; n = 3). The experiments were
repeated at least once with the similar design and results.
doi:10.1371/journal.pone.0087915.g009
Figure 10. Microglial TLR4 plays a critical role in HMGB1-
mediated ethanol neuroimmune activation. A: Minocycline,
known to inhibit microglial activation, was applied to HEC slices at
different concentrations during ethanol exposure (100 mM, 4 days).
Shown are mean 6 SEM of proinflammatory cytokine TNFa and IL-1b
mRNA levels. Blocking microglial activation by minocycline blunt
ethanol induction of cytokine TNFa and IL-1b mRNA (*p,0.01
compared with Control; #p,0.01 comparing to EtOH; n = 3). The
experiments were repeated twice with similar design and results. B:
Knocking down microglial TLR4 or neuronal HMGB1 with specific siRNA
abolished ethanol neuroimmune activation. Shown are mean 6 SEM of
proinflammatory cytokine TNFa and IL-1b mRNA levels relative to
control group treated with negative control siRNA (*p,0.001 compared
with Control; #p,0.0001 compared with EtOH; n= 3). The experiments
were repeated with similar designs and results.
doi:10.1371/journal.pone.0087915.g010
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increases release of acetylated HMGB1 that progressively increas-
es with time of ethanol treatment (Figure 7C). These results
indicate that ethanol decreases HDACs activity and increases
acetylated HMGB1 release, similar to TSA or MS-275, suggesting
a possible involvement of HDAC activity in controlling HMGB1
release from neurons.
Exogenous HMGB1 Induces Proinflammatory Cytokine
Expression through TLR4 Activation
To investigate the action of released HMGB1 by ethanol, we
first performed a set of experiments to determine the proin-
flammatory activity of exogenous HMGB1. Treatment of HEC
slices with exogenous HMGB1 increased proinflammatory cyto-
kine TNFa and IL-1b mRNA level by several fold (Figure 8). The
TLR4 antagonist, Rhodobacter sphaeroides LPS (Lps-Rs) [28] as well
as TLR4 siRNA knockdown significantly reduces HMGB1
induction of proinflammatory cytokine genes. Interestingly,
naltrexone (250 fM), the opiate antagonist recently found to block
TLR4 receptors [29] also blocked HMGB1 induction of TNFa
and IL-1b mRNA (Figure 8). These studies support the hypothesis
that HMGB1 activates TLR4 receptors inducing TNFa and IL-1b
mRNA.
HMGB1 Mediates Ethanol Induction of Proinflammatory
Genes through Microglial TLR4
Previous studies have suggested that brain HMGB1, TLR4
receptors and microglia are critical components of ethanol
induction of proinflammatory genes [12]. To explore the role of
ethanol released HMGB1 in induction of proinflammatory genes
we used HMGB1 neutralizing antibodies and inhibitors. Ethanol-
increased mRNA levels of both TNFa and IL-1b were blunted by
the addition of HMGB1 neutralizing antibodies (Figure 9A).
Glycyrrhizin is a natural product from licorice with anti-
inflammatory properties linked to binding and inactivation of
HMGB1 [30]. Glycyrrhizin addition to slices reduced ethanol
induction of TNFa and IL-1b (Figure 9B). Ethanol induction of
IL-1b varied between 5 and 12 fold in these two experiments. This
pronounced induction by ethanol was reduced to near or below
baseline levels by HMGB1 neutralizing antibodies and inhibitor
glycyrrhizin respectively, suggesting released HMGB1 mediates
ethanol inflammatory response.
Previous studies have suggested TLR4 receptors on microglia
are critical to ethanol induction of proinflammatory genes
[2,31,32]. In experiments investigating ethanol induced sensitiza-
tion of TLR agonist activation of brain microglia and neurotox-
icity in mice, we found minocycline, an inhibitor of microglial
activation [33,34], reduces both morphological microglial activa-
tion and markers of neuronal death [35]. We report here that
increasing concentrations of minocycline blunted ethanol induc-
tion of TNFa and IL-1b in a concentration dependent manner
(Figure 10A). Further, gene knockdown using HMGB1siRNA or
TLR4siRNA blocked ethanol induction of TNFa and IL-1b
mRNA (Figure 10B). We also tested naltrexone which has recently
been found to interact with the TLR4 receptor as well as the
opiate receptor [29]. We tested both optical isomers of naltrexone
since the (2) isomer is both an opiate receptor antagonist and a
TLR4 antagonist whereas the (+) isomer is only a TLR4
antagonist and not an opiate antagonist. Both (2) and (+)
naltrexone effectively blocked ethanol induction of proinflamma-
tory genes (Figure 11A and B). These studies are consistent with
previous studies that inflammatory activity of ethanol is medicated
by HMGB1 released from neuronal cells [36]. Minocycline
antagonism suggests ethanol released HMGB1 from neurons
may initiate proinflammatory responses through activation of
microglia TLR4, however, the mechanisms of minocycline
inhibition of microglial activation are poorly understood and
linked to inhibition of p38 kinase activation [34]. Some neurons
express p38-kinase [37] and it is possible that minocycline also
impacts neuronal neuroimmune signaling. Additional studies are
needed to clearly define the brain cell types responding to
HMGB1 release. These studies are consistent with previous studies
that inflammatory activity of ethanol is medicated by HMGB1
released from neuronal cells. Minocycline antagonism suggests
ethanol released HMGB1 from neurons may initiate inflammatory
response through activation of microglia TLR4.
Discussion
HMGB1 is a ubiquitous protein that is highly expressed in
neurons [12,22]. We report here that ethanol and HDAC
inhibitors release acetylated HMGB1 from neuronal cells in
HEC slice cultures. It is possible that osmotic effects of added
ethanol contribute to HMGB1 release, although visual inspection
of ethanol treated neurons in Fig. 2 do not show swelling and
acetylated HMGB1 is released supporting an active mechanisms of
HMGB1 release, we cannot rule out an osmotic effect. Our data
further indicates that ethanol-induced expression of proinflamma-
Figure 11. TLR4 antagonist naltrexone blocks ethanol neu-
roimmune activation. A: Ethanol (100 mM, 4 days) induction of
proinflammatory signaling molecules were significantly blocked by
TLR4 antagonist naltrexone (minor form, 250 fM). Shown are mean 6
SEM of mRNA levels relative to control (*p,0.001 compared with
Control; #p,0.01 compared with Ethanol; n = 3). B: Ethanol induction
of TNFa and IL-1b mRNA is completely blocked by naltrexone (plus
form, 250 pM) (*p,0.001 compared to Control; #p,0.0001 compared
with EtOH; n = 3).
doi:10.1371/journal.pone.0087915.g011
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tory cytokines TNFa and IL-1b was blunted by the blockade of
both HMGB1 using HMGB1 neutralizing antibodies and
inhibitors and TLR4 using TLR4 siRNA and TLR4 antagonists
including Lps-Rs and naltrexone, consistent with HMGB1 release
activating TLR4 receptors. Consistent with our finding in HEC
slices, HMGB1 treatment of neuronal-astrocyte cultures induces
HMGB1 mRNA as well as proinflammatory cytokines without
increasing PI assessed cell death, although HMGB1 did sensitize to
glutamate excitotoxicity [38]. Our findings for the first time
indicate that neurons release HMGB1 through an active
mechanism related to changes in status of HMGB1 acetylation
that is regulated by HDACs activity, consistent with studies in
monocytes and hepatocytes that find HMGB1 acetylation
regulates movement from the nucleus to cytoplasm and subse-
quent release [18,19]. HDACs regulation of HMGB1 acetylation
may represent an important regulator of neuronal HMGB1
release. These novel findings suggest active release of HMGB1
being an endogenous TLR4 ligand contributing to ‘‘sterile’’
neuroimmune activation in brain by ethanol (Figure 12).
HMGB1, TLR4 receptors and/or neuroimmune activation are
linked to many brain diseases including depression [39] and
neurodegeneration [40]. For example, in animal models of stroke,
HMGB1 is released rapidly before pronounced cell death [41] and
treatment with neutralizing HMGB1 antibodies or HMGB1
inhibitor glycyrrhizin reduces ischemia-induced neuroimmune
gene induction and brain damage [42,43,44] as well as spinal cord
damage [44]. Our findings indicate HMGB1 release activates
TLR4 inducing proinflammatory cytokines TNFa and IL-1b.
Since HMGB1 is predominantly localized in neuronal cells, our
studies suggest ethanol and HDAC inhibitors release HMGB1
from neurons. Recent studies have found that neuronal excitation
releases HMGB1 activating glial TLR4 receptors that contribute
to the generation and perpetuation of epileptic seizures [23]. Our
findings extend these studies to ethanol release of HMGB1 and
may suggest a key role of HMGB1 in persistent and progressive
brain neuroimmune activation (Figure 12). We have previously
found that brain neuroimmune activation persists for long periods
that contribute to neurodegeneration [10,12,31,35]. It is conceiv-
able that neurons release danger signal HMGB1 in response to
stimuli and HMGB1 initiates crosstalk of neuroimmune signaling
between neurons and glia. The findings reported here support the
notion that positive feedback loops of neuroimmune activation in
brain may require HMGB1 activation of microglial TLR4
resulting in production of microglia-released proinflammatory
mediators such as TNFa and IL-1b, which further augments
release of HMGB1 from neurons and other cells (Figure 12). This
is consistent with studies finding that mice lacking TLR4 are
protected against brain insults including models of ischemia,
trauma, genetic neurodegeneration and epilepsy as well as alcohol
and toxin induced neuropathology [2,40,45].
Accumulating evidence from a broad range of studies supports
neuroimmune activation as important contributing factors to
alcoholism. Indeed, study of post-mortem human alcoholic brain
has found increased microglial markers and the proinflammatory
molecules [3,4] as well as increased expression of HMGB1 and
TLR receptors [12]. Chronic ethanol treatment of mice also
increases brain proinflammatory gene expression [5] as well as
HMGB1 and TLR4 expression [12]. Mice with genetic predispo-
Figure 12. Schematic of ethanol-induced release of neuronal HMGB1 activating microglial TLR4 and creating a positive feedback
loop that amplifies innate immune cascades. Ethanol exposure decreases neuronal HDACs activity causing increased acetylation of HMGB1.
Acetylated HMGB1 is mobilized into cytosolic compartment and subsequently secreted into extracellular space. Extracellular HMGB1 activates TLR4 in
microglia to initiate neuron-glia neuroimmune communication by producing a wide array of proinflammatory cytokines or mediators such as TNFa,
IL-1b, iNOs and MCP-1. Activated microglia may also induce expression and release of HMGB1 [56,57]. Proinflammatory cytokines and extracellular
HMGB1 create a positive feedback loop that amplifies neuroimmune responses with engagements of other TLRs and RAGE as well as individual
cytokine receptors across cell types. In addition, extracellular HMGB1 can exert potent proinflammatory activity by forming complexes with
proinflammatory cytokines TNFa and IL-1b (unpublished data). Targeting multiple sites involving in HMGB1-TLR4 signaling may prove to be effective
therapeutic approaches for combating brain neuroimmune activation associated with alcoholism and drug addiction [1,47].
doi:10.1371/journal.pone.0087915.g012
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sition for high alcohol consumption as well as human alcoholics
show changes in brain expression of genes related to immune
signaling [46]. Studies of the genetic determinants of high
voluntary alcohol drinking across multiple mouse strains have
found NF-kB and proinflammatory cytokine signaling genes
among the molecular determinants [8]. Human genetic associa-
tion studies find multiple alleles of neuroimmune genes, including
NF-kB are associated with alcoholism [1,47]. Mice lacking
neuroimmune genes including genes important for TLR4
signaling, e.g. CD14, have a lower preference and drink less
alcohol [46]. Recent studies indicate that mice treated with LPS
inducing brain neuroimmune gene induction drink more alcohol
than controls for long periods [9]. Transgenic mice lacking TLR4
receptors do not show ethanol induced activation of proinflam-
matory genes in astrocytes [48] or microglial cultures [32].
Chronic ethanol treatment of mice lacking TLR4 receptors
similarly finds reduction of ethanol-induced brain proinflamma-
tory gene expression, neurodegeneration, dopamine alterations
and alcoholic behavioral pathologies [6,49] and damage to myelin
[49]. In previous studies we found ethanol treatment of HEC slice
cultures increased proinflammatory transcription factor NF-kB-
DNA binding and expression of NF-kB target genes TNFa, IL-1b,
MCP1 and iNOS [7,50]. The present study for the first time
identifies that endogenous danger signal HMGB1 can be
mobilized from neurons, translocate into cytoplasmic compart-
ments and subsequently released into extracellular space upon
ethanol exposure. Neuronal HMGB1-microglia TLR4 signaling
may be the centerpiece of innate immunity in brain in response to
alcohol consumption. We report here that ethanol responses can
be effectively attenuated by either HMGB1 antagonism or TLR4
antagonism. It is worth mentioning here that naltrexone, an opiate
receptor antagonist recently found to be a TLR4 antagonist [29],
blocks ethanol-HMGB1 activation of proinflammatory signaling.
Naltrexone is used as a pharmacotherapy for alcoholism [51] and
brain neuroimmune activation has been suggested to contribute to
addiction [52]. Naltrexone could alter neuroimmune responses
through opiate antagonism and/or through TLR4 receptor
antagonism. Together, these studies are consistent with
HMGB1-TLR4 activation of neuroimmune signaling as contrib-
uting factors to alcoholism and alcoholic neuropathology. Our
findings may provide insight into existing therapeutics and/or may
represent new treatment targets for alcoholism.
We report here that HDAC inhibitors release acetylated
HMGB1 from HEC brain slice cultures and increase cytosolic
HMGB1, HDAC1 and HDAC4. Ethanol also released acetylated
HMGB1 and increased cytosolic HMGB1, HDAC1 and HDAC4.
Previous studies have shown ethanol treatment of mice decreases
brain HDAC activity [53]. Other studies in rats also report
increases in brain histone acetylation associated with increased
histone acetyltransferase activity that is potentiated by HDAC
inhibitors [54]. Ethanol inhibition of HDAC in amygdala
increases histone acetylation associated with the anxiolytic actions
of ethanol [55]. We found that ethanol treatment decreased
HDAC1/4 mRNA levels acompanying with increase in release of
acetylated HMGB1. Similarly, studies in hepatocytes and mono-
ncytes demonstrate nuclear HDAC activity modulates HMGB1
acetylation and cytoplasmic translocation and subsequently release
[18,19]. Together these studies support the hypothesis that
alterations in acetylase enzymes regulate HMGB1 release and
neuroimmune activaton in brain.
Conclusions
In summary, we find that HMGB1 is highly expressed in
neurons in HEC cultures and ethanol decreases HDAC activity
triggering releases of neuronal HMGB1 (Figure 12). Extracellular
HMGB1 subsequently activates microglial TLR4 leading to
production of proinflammatory cytokines TNFa and IL-1b.
Targeting either HMGB1 using HMGB1 neutralizing antibodies
and inhibitor glycyrrhizin or TLR4 using TLR4 antagonists,
TLR4 siRNA can effectively attenuate ethanol inflammatory
response (Figure 12). These findings suggest multiple new potential
targets to block brain neuroimmune activation, alcoholic neuro-
degeneration and alcoholism.
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